New Delhi, 9 Nov 2013: The National Pharmaceutical Pricing Authority (NPPA), which has been revising the prices of essential medicines in accordance with the new Drug Price Control Order, 2013 since June this year, has fixed the prices of 63 more formulation packs. With this, the total number of formulation packs covered under the new pharmaceutical policy has crossed 400, including over 50 packs whose prices could not be revised as information was not available. The price regulator had already announced the new prices for over 300 formulation packs already. According to the new pricing policy, the ceiling of prices are fixed based on the simple average of the prices of all brands of that drug that have a market share of atleast one per cent. The national list of essential medicines lists 348 bulk drugs, which are sold as 650 formulations. |
Monday, November 11, 2013
NPPA revises prices of 63 more formulation packs under new DPCO
60 drug cos offer increased margins to trade on controlled drugs after talks with AIOCD
Mumbai, 11 Nov 2013: Over 60 drug manufacturers have agreed to increase trade margins of wholesalers and retailers on price controlled medicines after a series of talks between various industry bodies and All India Organisation of Chemists and Druggists (AIOCD). AIOCD had to initiate talks with the industry bodies as Department of Pharmaceuticals (DoP) has been hesitant to restore the old trade margins by amending DPCO 2013. Says Suresh Gupta, general secretary, AIOCD, "We look forward to getting an increase in the trade margin from over 90 companies for which talks are still going on." |
Saturday, November 9, 2013
DoP asks NPPA to relook at ceiling price fixed for azithromycin under new DPCO
New Delhi, 31 Oct 2013: The National Pharmaceutical Pricing Authority (NPPA) has been directed by the Department of Pharmaceuticals (DoP) to reconsider the ceiling price fixed for Zithrox and Azilide brands of azithromycin produced by Alembic Pharmaceuticals Ltd., following a review petition filed by the company against the NPPA revision as per the new Drug Price Control Order, 2013. However, the review petitions by Modi-Mundipharma Pvt Ltd and Win-Medicare Pvt Ltd were rejected by the DoP as many more companies have reportedly challenged the new ceiling prices announced by the NPPA in line with the DPCO and the pharmaceutical pricing policy in the recent months. |
After HC disallows ban, govt to put warning on anti-depressant
New Delhi, 6 Nov 2013: Left red-faced after yet another drug ban order failed to pass judicial scrutiny, the government is set to pass an order that anti-depressant Deanxit should be sold with a warning in red that the drug is to be sold only on the prescription of a registered psychiatrist. A notification regarding this will soon be issued under section 26A of the Drugs and Cosmetics Act. In addition, an expert committee comprising psychiatrists and pharmacologists constituted by the Drug Technical Advisory Board will examine the safety and efficacy of the drug and make recommendations about its marketing in India. |
SHRI K.E.PRAKASH PRESIDENT KCDA AT.............
On this occasion Shri Rajshekhar Malli (Asst.Drugs Controller of Belgaum circle) and Shri K.S.Mallikarjun(Asst.Drugs Controller of Karwar cicle) will guide about the amendments in Drugs & Cosmetics rules.
Talking with Belgaum Chemist Blog,Shri Gangadhar Turmundi,Secretary of the Association briefed the Successful Activities of the Association,like Solving problems of wholesale distributors,Retail Members.Also by circulating Important circulars about Rules& Regulations of Drug & Cosmetic Act 1940,Vat circulars time to time.In coming days Association is arranging Education Programmes for their Members.
Subscribe to:
Posts (Atom)